Aplastic anemia is a rare disorder with an incidence of~2-4 cases per million people per year. 1 If left untreated, only 30 percent of aplastic anemia patients will survive after 1 year, and the rest will die from complications of pancytopenia. 2 Options for definitive therapy for aplastic anemia include hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy. 3 Bone marrow transplantation (BMT) is considered the treatment of choice in patients younger than 20 years due to better overall survival (OS) and the preferred treatment in healthy patients older than 20 years of age with a fully HLA-matched sibling donor. 4, 5 As GvHD is the principal cause of morbidity and mortality after HSCT in patients with aplastic anemia, 6 the choice of suitable source of stem cell for transplantation is very important.
This study included 185 patients with aplastic anemia who were referred to our center between 1991 and 2013 to compare the results of BMT and peripheral blood stem cell transplantation (PBSCT). Forty patients (median age 17.5 years) received BMT and 145 patients (median age 24) received PBSCT. All participants received HSCT from a fully HLA-matched sibling donor. Patients conditioned by cyclophosphamide 50 mg/kg once daily i.v. for 4 days for BMT and PBSCT plus Anti-thymocyte globulin (ATG: Thymoglobulin, Genzyme) 2.5 mg/kg/ i.v. on days − 4 till − 2 for BMT and PBSCT and 17 other patients received cyclophosphamide alone. Prophylaxis for GvHD consisted of cyclosporine (1.5 mg/kg intravenously from − 3, then 3 mg/kg/day intravenously from +7 in PBSCT and +11 in BMT then 12.5 mg/kg/day per oral) alone or plus a short course of methotrexate (10 mg/m 2 on Day +1 and 6 mg/m 2 on Days +3, +6, and +11). Cyclosporine was started 3 days prior to transplantation and continued orally for 6 to 7 months post HSCT; it was then discontinued in the absence of GvHD.
Patients followed-up beyond 5 years were censored to better compare the two groups because the PBSCT group had a shorter follow-up period. Univariate analysis was used to assess the independent variables (Table 1 ) and only significant variables in univariate analysis were included in the multivariate analysis ( Table 2 ). The median follow-up was 60 (confidence interval (CI): 47.8-63.1) months for the BMT group versus 49.7 (CI: 41.9-58.2) months for the PBSCT group. The 5-year disease-free survival (DFS) was 52.3% and 73.5% in the BMT and PBSCT groups, respectively (hazards ratio (HR) = 0.45, P-value = 0.007, CI = 0.25-0.80) which means that PBSCT protected against relapse in our patients. The 5-year OS was 72.5% and 78.2% in the BMT and PBSCT groups, respectively (HR = 0.72, P-value = 0.36, CI = 0.36-1.45). Eleven (27.5%) patients in the BMT group and 8 (5.5%) patients in the PBSCT group experienced relapse after transplantation. Eleven (27.5%) patients in the BMT group and 29 (20.0%) patients in the PBSCT group expired during the study. The most common causes of death were GvHD in both groups.
According to multivariable analysis of DFS, the risk of death or relapse in the PBSCT group was one-third of death risk or relapse in the BMT group (HR = 0.4, P-value = 0.003) which means that PBSCT was protective based on adjusted results. Also, the adjusted results showed that with an increase in the time between diagnosis and transplantation the risk of death or relapse increased (HR = 2.24, P-value = 0.007) significantly. Multivariable analyses of OS revealed that PBSCT group had a hazard of death about half of hazard of death of BMT group (HR = 0.51, P-value = 0.084). Also, the adjusted results showed that a prolonged interval between diagnosis and transplant significantly increased the risk of death in patients (HR = 2.32, P-value = 0.011), while the effect of age at transplantation was not significant (HR = 1.03, P-value = 0.126).
Twenty-four (60.0%) patients in the BMT group and 77 (53.1%) patients in the PBSCT group developed acute GvHD (P-value = 0.438). The cumulative incidence of chronic GvHD was 25.7 and 51% in the BMT and PBSCT groups, respectively, within two years after transplantation (P-value = 0.014). Limited chronic GvHD was more common among the patients of both groups. There was no significant relationship between the incidence of acute GvHD and patients' age at transplantation. In the cohort of patients, chronic GvHD occurs more frequently in elderly patients, showing no association with stem cell sources.
The mobilized PBSCs contain a higher number of CD34+ cells and a higher total number of lymphoid subsets about 3-to 4-fold and 10-fold, respectively. 7 The analysis of gene expression profiles revealed functional differences between human CD34+ hematopoietic cells of the blood and marrow. 8 These findings explain different outcomes of transplantation using BM and PBSCs. Since aplastic anemia is a non-malignant hematologic disease, the incidence of GvHD has no benefits for patients 9 and leads to complications and even death. The incidence and severity of GvHD after transplantation are highly dependent on the choice of the stem cell source, showing the incidence of GvHD is statistically greater with PBSCT.
A report from Schrezenmeier et al. 10 (n = 692) showed that 5-year OS in the PBSCT and BMT groups aged below 20 years was 73% and 85%, respectively (statistically significant), while for patients over 20 years of age it was 52% for the PBSCT group and 64% for the BMT group (statistically non-significant). There was no statistically significant difference between the two treatment groups in the incidence of acute GvHD. The incidence of chronic GvHD was higher in PBSCT patients o 20 years of age, but no differences were found in patients over the age of 20 years. However, the results of a study carried out by Bacigalupo et al.
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(n = 1886) revealed that BMT had statistically superior survival compared to PBSC in all age groups and GvHD -related mortality and the incidence of acute and chronic GvHD were statistically higher in PBSC recipients.
According to Schrezenmeier et al., 10 the use of PBSCT has increased in recent years in the majority of centers, but bone marrow was the preferable graft source in recipients involved in previous studies, so there are insufficient data to support the use of PBSCT.
The results of our study indicated that 5-year DFS was significantly higher in peripheral blood recipients, showing the preference of peripheral blood stem cells over bone marrow to prevent disease relapse. The better outcomes in survivals were achieved, while the patients in the PBSCT group had high risk factors such as old age, received more blood and platelet and have more interval time from diagnosis till transplantation.
The rate of relapses has decreased to 10% in aplastic anemia by controlling transplant-related complications and improving treatment methods. 11 Indeed, one of the problems after transplantation is that more relapses occur in patients who receive more blood and/or platelets. The risk of relapse is as high as about 30% in patients with a long interval between diagnosis and transplantation. 12 It seems that despite of the same rate of sever chronic GvHD, transplantation failure rate and the relapse risk have significantly decreased in our patients, compared to BM patients. It makes an important and significant advantage for our practice of PBSCT in high risk patients.
The short hospital stay is another important consideration. Compared to BMT, PBSCTs are associated with faster engraftment, leading to earlier discharge. In the present study, the median duration of hospital stay for PBSCT was statistically significantly shorter.
The benefits of PBSCT for patients appear to be a decrease in the relapse rate and if the incidence and severity of GvHD are managed, PBSCT must be considered in these patients especially for those in high risk groups. In order to prevent GvHD after transplantation, more effective methods should be developed. However, a randomized trial study would allow future researchers to better compare these two transplantation sources. Abbreviations: ATG = anti-thymocyte globulin; CI = confidence interval; CIF = cumulative incidence function; EBMT = European Society for Blood and Marrow Transplantation; PLT = platelet; RBC = red blood cell complete blood count; TRM = transplant-related mortality. Letter to the Editor
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